- Home
- ACTU vs RAPT Comparison
ACTU vs RAPT Comparison
Compare ACTU & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- RAPT
- Stock Information
- Founded
- ACTU 2015
- RAPT 2015
- Country
- ACTU United States
- RAPT United States
- Employees
- ACTU N/A
- RAPT N/A
- Industry
- ACTU
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ACTU
- RAPT Health Care
- Exchange
- ACTU NYSE
- RAPT Nasdaq
- Market Cap
- ACTU 135.0M
- RAPT 117.5M
- IPO Year
- ACTU 2024
- RAPT 2019
- Fundamental
- Price
- ACTU $8.00
- RAPT $0.79
- Analyst Decision
- ACTU Strong Buy
- RAPT Hold
- Analyst Count
- ACTU 1
- RAPT 7
- Target Price
- ACTU $20.00
- RAPT $5.00
- AVG Volume (30 Days)
- ACTU 42.0K
- RAPT 1.1M
- Earning Date
- ACTU 05-21-2025
- RAPT 05-08-2025
- Dividend Yield
- ACTU N/A
- RAPT N/A
- EPS Growth
- ACTU N/A
- RAPT N/A
- EPS
- ACTU N/A
- RAPT N/A
- Revenue
- ACTU N/A
- RAPT N/A
- Revenue This Year
- ACTU N/A
- RAPT N/A
- Revenue Next Year
- ACTU N/A
- RAPT N/A
- P/E Ratio
- ACTU N/A
- RAPT N/A
- Revenue Growth
- ACTU N/A
- RAPT N/A
- 52 Week Low
- ACTU $5.51
- RAPT $0.79
- 52 Week High
- ACTU $11.73
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- RAPT 31.31
- Support Level
- ACTU N/A
- RAPT $0.81
- Resistance Level
- ACTU N/A
- RAPT $0.98
- Average True Range (ATR)
- ACTU 0.00
- RAPT 0.10
- MACD
- ACTU 0.00
- RAPT -0.03
- Stochastic Oscillator
- ACTU 0.00
- RAPT 7.72
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.